Bull Case

Landmark Sandoz Transaction: The sale of Just - Evotec Biologics Toulouse to Sandoz for approximately US$350 million in cash, plus an indefinite technology license, immediately improves Evotec's earnings, capital efficiency, and profit margins. The deal also includes potential license fees and development revenues exceeding US$300 million, and royalties on up to ten biosimilars, targeting a market with over US$90 billion in originator net sales.

Strategic Partnerships and Pipeline Progress: Evotec's strategic collaborations, such as with Bristol Myers Squibb, continue to deliver milestone payments (e.g., US$5 million for FDA IND clearance), and the company expects up to four molecules to enter Phase II trials within nine months, supporting future revenue and valuation growth.

Asset-Lighter, Technology-Driven Model: Transitioning to an asset-lighter business model and better monetization of proprietary technology platforms positions Evotec for higher margins and scalable growth, reducing capital intensity and enhancing long-term profitability.

Evotec's strong execution on strategic asset sales, high-value partnerships, and a shift toward a technology-driven, asset-lighter model create a foundation for margin expansion and robust long-term growth, with significant upside from pipeline and royalty streams.

Base Case

Soft Demand in Discovery & Preclinical Segment: The Discovery & Preclinical Development (D&PD) segment continues to face soft demand, with segment revenues down 12.3% year-over-year, limiting near-term revenue growth and weighing on group performance.

Stable Core Revenue and Confirmed Guidance: Despite headwinds, group revenues remain substantial (€535.1 million for 9M 2025), and management has reaffirmed both 2025 guidance and the 2028 outlook, indicating operational stability and resilience.

Profitability and Leverage Constraints: Evotec's operating profit margin remains negative (-8.7% TTM), and key leverage metrics (e.g., negative net debt to EBITDA, negative interest coverage) reflect ongoing profitability and capital structure challenges, though the Sandoz transaction is expected to improve these metrics.

Evotec is positioned for moderate growth, supported by a stable revenue base and strategic partnerships, but faces ongoing profitability and demand challenges in core segments. Execution on asset sales and technology monetization is critical to offsetting these headwinds.

Bear Case

Persistent Profitability Challenges: Evotec's negative operating profit margin and weak free cash flow yield (1.2% TTM) highlight ongoing structural profitability issues, which could persist if cost discipline or margin expansion from asset sales underperform.

Execution and Integration Risks: The successful realization of value from the Sandoz transaction and technology licensing depends on effective execution and integration. Delays or underperformance in biosimilar royalty streams or milestone payments could impair the expected financial uplift.

End-Market and Funding Headwinds: Continued softness in early drug discovery demand and potential tightening of biotech funding could further pressure Evotec's core business, limiting growth and increasing reliance on external partnerships.

Evotec faces high risk if profitability does not improve post-asset sale, or if execution on new business models and royalty streams falters. Prolonged weakness in core demand or funding could further constrain financial flexibility.

Overall Score

Evotec demonstrates strong strategic positioning through high-value asset sales, a robust partnered pipeline, and a shift to a technology-driven, asset-lighter model. While profitability and demand headwinds persist, the company’s actions are likely to improve margins and capital efficiency, supporting a favorable risk-reward profile relative to peers.